Navigation Links
Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
Date:4/14/2009

the procedure, the patient's ejection fraction, a measure of the heart's pumping ability, more than doubled, the size of his ventricle was reduced by 22 percent and his ventricle wall thickness increased by 23 percent. By day eight, the patient was able to walk unassisted. He was subsequently discharged from the hospital in a considerably improved condition.

Prof. Dr. Bauernschmitt said, "We are extremely pleased with the initial outcome of the first patient treatment with Algisyl-LVR. The administration of this implantable biopolymer to the heart wall provides a practical new tool to prevent and even reverse the dilation of the left ventricle, which is typical in congestive heart failure. As such, this new therapy has the potential to provide significant health benefits to a growing population of patients. While it is still very early, the initial outcome of Algisyl-LVR suggests that the therapy is feasible and safe while it provides immediate, tangible benefits. We look forward to treating additional patients here at the German Heart Center."

Raymond W. Cohen, Symphony Medical chief executive officer said, "As one might imagine, the physician, the patient, and all of us at Symphony are quite energized with this remarkable result. Algisyl-LVR results from years of research and an exhaustive number of pre-clinical studies which demonstrated safety and impressive efficacy. Given that congestive heart failure is a lethal and complex disease, positive pre-clinical data does not always translate into success with humans; however, it is notable that there was an excellent correlation between our pre-clinical data and the first human results. We look forward to treating more patients and establishing Algisyl-LVR as an important new therapy to increase the quality of life of patients suffering from congestive heart failure."

About Symphony Medical, Inc.

Symphony Medical, founded in 2003, is a p
'/>"/>

SOURCE Symphony, Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Symphony Managemnt Consulting Hires New Solutions Director
2. Angiotech and Symphony Medical Announce Licensing Agreement
3. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
4. NeoStem Completes $11 Million Private Placement Financing to Support Expansion Activities in China, Further Development of NeoStems VSEL Technology and Advancement of Medical Tourism Initiatives
5. Ventus Medical Appoints John McCutcheon as President and CEO
6. New security and medical sensor devices made possible by metallic nanostructures
7. Council for American Medical Innovation Brings U.S. Leaders in Medicine, Biotechnology and Discovery Together in Chicago for Best and Brightest Forum on Medical Innovation
8. China Sky One Medical, Inc. Provides Update on Filing Form 10-K
9. SPO Medical Files Annual Report for Fiscal 2008
10. ArunA Biomedical Submits Contract Proposal to Further Develop Environmental Biosensor for National Security
11. ArunA Biomedical Awarded Department of Defense Contract to Further Develop Environmental Biosensor for National Security
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... York, NY (PRWEB) December 16, 2014 ... significant changes since 2013, which is why IBISWorld updated ... this industry continues to benefit from an intensified focus ... the proposal for new emission standards for power plants ... industry operators. According to IBISWorld Industry Analyst Sarah Kahn, ...
(Date:12/17/2014)... Washington, USA (PRWEB) December 16, 2014 ... Baum, manager at Philipps- Universität Marburg’s Department of ... and photonics, in the newly released SPIE ... “And never be too shy to ask questions.” ... (science, technology, engineering, and mathematics) occupations ranging from ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Ipsen ... IPN; ADR: IPSEY), today announced that ... to as Somatuline®) was approved by the U.S. ... of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients ... or metastatic disease to improve progression-free survival (PFS). ...
(Date:12/17/2014)... December 17, 2014 This report ... Quartz Tubing industry. For an overview analysis, the ... application, industry chain structure, industry overview, policy analysis, ... tubing industry has witnessed rapid development with ... of acquisitions. This report mentions quartz tubing upstream ...
Breaking Biology Technology:Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 82020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2
... Spherix Incorporated (Nasdaq: SPEX ), an innovator ... technical and regulatory consulting services to food, supplement, biotechnology ... Annual Meeting of Shareholders. , At the meeting, shareholders ... following members to the Board of Directors: , ...
... /PRNewswire/ - Aegera Therapeutics Inc. announced today the dosing ... study of AEG35156, a targeted antisense therapeutic in mid-stage ... "An Open-Label Randomized Phase 2 Study of the X-Linked ... with High-dose Cytarabine and Idarubicin in AML Following Failure ...
... ... ... 16, 2009 -- Popular Science Magazine has named the Lyric “invisible” hearing aid from ... Health category.    Chosen from thousands of entrants, Lyric is designed to reside deep in the ...
Cached Biology Technology:Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 3
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a leading ... that its DigitalPersona ® Pro Enterprise software ... been deployed throughout First Bank branch locations in ... South Carolina and Virginia. First Bank, a ... Southern Pines, North Carolina , selected the ...
(Date:11/21/2014)... November 18, 2014 According to ... by Systems (Video, RFID, Access Control, Intrusion Detection, Parking ... Banks, Government), Component Service Geography - Global Forecasts to ... is projected to be around $25 Billion in 2014 ... growing at a CAGR of 8.69%. Browse ...
(Date:11/21/2014)... C-Labs LLC, a leading provider of remote ... today announced the appointment of John Traynor ... strategic advisor to the firm, Mr. Traynor will now ... based out of the C-Labs office in ... Muench , Chief Executive Officer. Photo - ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... Seabirds are the surprising culprits in delivering pollutants ?through ... Canadian study shows. , The most common form of ... most of the human-made contaminants to some coastal ecosystems, ... of pollutants such as mercury and DDT to as ...
... Medical Institute researchers have discovered a novel way in ... regulated. They have identified a signaling pathway that controls ... cleaved during development. , The way these cells are ... of neurogenesis, vertical cleavage gives rise to two mature ...
... clarify how one of the body's molecules controls the trafficking ... to tissues to fight infection -- a crucial response that ... autoimmune diseases. , The traffic control system -- composed of ... cells -- usually prevents T cells from launching harmful reactions. ...
Cached Biology News:Industrial contaminants spread by seabirds in High Arctic, new Canadian study shows 2Brain size may depend upon how neural cells are cleaved 2Brain size may depend upon how neural cells are cleaved 3Discovery of T-cell 'traffic control' boosts new drug promise 2Discovery of T-cell 'traffic control' boosts new drug promise 3Discovery of T-cell 'traffic control' boosts new drug promise 4
...
Experion spin filters are used to filter the gel matrix and gel stain solution prior to use with the Experion automated electrophoresis system. Supplied as 10 spin filters....
...
... to PRKAR2 cAMP is a signaling ... functions. cAMP exerts its effects by activating ... the signal through phosphorylation of different target ... a tetramer composed of two regulatory and ...
Biology Products: